CJC-1295, sermorelin, and ipamorelin are often grouped in catalogs and secondary articles. They are not one material. The original overview of this page asks readers to keep a GHRH analogue distinct from a ghrelin-receptor agonist, to label DAC, no-DAC, and sequence variants correctly, and to use matched concentration and time-course controls when more than one analogue appears in the same file.
Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not a ranking, not claims about a Velnacor lot, and not instructions for use in people or animals.
Two receptor families, not one “GH peptide” class
Sermorelin is a name for GHRH(1-29), the N-terminal fragment of growth hormone-releasing hormone. A 1999 review by Prakash and Goa summarized published clinical literature on sermorelin in the diagnosis and treatment of children with idiopathic GH deficiency (Prakash and Goa, 1999). That review is cited here for identity and for the existence of a published clinical-research record. It is not a protocol, and it is not applied to any other analogue on this page.
CJC-1295, in the primary papers verified for this draft, is a long-acting GHRH(1-29) analogue designed to conjugate to serum albumin (the DAC form) and was shown to activate the GRF receptor in rat pituitary work (Jetté et al., 2005). In a later healthy-adult study, Teichman and colleagues reported prolonged GH and IGF-I secretion after CJC-1295 (Teichman et al., 2006). Those are findings for the DAC analogue in the models of those papers. They do not document a no-DAC SKU, and they are not use instructions.
Ipamorelin is a pentapeptide GHSR (GHRP-like, ghrelin-receptor) agonist. Raun and colleagues reported GH release from rat pituitary cells and in rat and swine models, with ACTH and cortisol responses in swine that did not differ significantly from GHRH, unlike GHRP-6 and GHRP-2 in the same design (Raun et al., 1998). That selectivity finding belongs to ipamorelin’s receptor class. It is not a reason to file ipamorelin and a GHRH analogue as interchangeable.
Identity pages for two of the three names are What Is CJC-1295? and What Is Ipamorelin?.
DAC, no-DAC, and sequence-variant labeling
If a file uses the name CJC-1295, it should state whether the DAC modification is present. A no-DAC analogue, sermorelin (GHRH 1-29), and a DAC-modified analogue are different materials. Combination SKUs, if offered, are additional rows. Shared shipping or a single invoice total does not merge receptor classes or modification states.
| Name | What the cited literature identifies | What not to assume |
|---|---|---|
| Sermorelin | GHRH(1-29), as reviewed in published clinical literature (Prakash and Goa, 1999). | That a GHRH fragment is the same material as a DAC-modified analogue. |
| CJC-1295 (DAC) | A long-acting hGRF(1-29) analogue designed for albumin conjugation (Jetté et al., 2005; Teichman et al., 2006). | That a no-DAC catalog SKU is documented by those papers. |
| Ipamorelin | A GHSR/GHRP-receptor pentapeptide with reported GH selectivity in the models of Raun et al. (Raun et al., 1998). | That GH release in one receptor class predicts the other. |
Matched controls and separate lot files
When more than one analogue is studied or purchased, concentration basis, time-course, and documentation should be specified per material. A complete report for one row does not document another. How to Read a Peptide COA, lot traceability, and How to Evaluate a Peptide Supplier: B2B Checklist apply independently to each line item.
Catalog records exist for sermorelin, ipamorelin, and both DAC and no-DAC CJC-1295 forms, as well as some combination SKUs. There is not a standalone public landing page for every name; use the product directory and the COA Library, then confirm each SKU in the inquiry. For packing at supply scale, see wholesale peptides.
No pooled ranking
A single peer-reviewed study that compared CJC-1295, sermorelin, and ipamorelin head-to-head in one experimental design was not verified for this draft. The comparison is therefore a documentation framework built from identity papers and from findings reported for each analogue in its own literature. It is not a pooled efficacy table, and it is not a reason to transfer a result from one row to another.
Time-course and concentration controls should be defined per analogue if more than one material appears in the same laboratory plan. Published time-course work on one analogue, such as the ipamorelin volunteer modeling study, does not set the sampling design for a different receptor class.
What this comparison does not decide
Nothing on this page ranks the three analogues, recommends one over another, or describes a laboratory or clinical procedure. The practical result of a careful comparison is a cleaner file: three named identities, separate document chains, and no transferred conclusions.
Selected published literature
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. doi:10.2165/00063030-199912020-00007. PubMed 18031173. Review article; cited for identity and the published clinical-research record, not as a use instruction.
- Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286. PubMed 15817669.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536. PubMed 16352683. Cited as published clinical-research observations, not as a use instruction.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PubMed 9849822.
Sourcing notes for qualified buyers
Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.
Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.
Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.